Bruker Corporation (BRKR) Fair Value 2026

BRKR · Laboratory Analytical Instruments ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.5 /10

32 fundamental signals · 12 models active

Value Trap Risk

LOW (25/100)

Quick Summary — As of 2026-07-13, Bruker Corporation (BRKR) trades at $58.97, approximately 566% above CirclFi’s Bayesian DCF fair value of $8.85. QOC: 8.5/10. Value Trap Risk: 25/100 (LOW). 12/13 models active.

Key Facts

Ticker
BRKR
Price
$58.97
Quality Score
8.5/10
Value Trap Risk
25/100
Models Active
12/13
Last Updated
Strength: First Chicago suggests +21.4% upside with 58% confidence
Risk: Majority of models suggest overvaluation

Valuation Matrix

12 Intrinsic Value Models vs. Current Price ($58.97)

Core Models (Unlocked)
Model Fair Value Upside
Bayesian DCF
High Conviction
$8.85 -85.0%
Earnings Power Value
High Conviction
$13.48 -77.1%
CUCE Ensemble
Low Conviction
$22.23 -62.3%
First Chicago
High Conviction
$71.57 +21.4%

Unlock the Full Matrix

Access 8 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 12 Models →

Cancel anytime · No contracts · Instant access

What Is Bruker Corporation (BRKR) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Bruker Corporation's intrinsic value is estimated at $27.40, suggesting the stock is overvalued at its current price of $58.97. With 10 out of 12 models flagging downside (-53.5% average return), the market may be pricing in unsustainable growth. Model dispersion is worth noting: First Chicago targets $71.57 (+21.4%), versus Markov DDM at $3.73 (-93.7%). This +115.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About BRKR?

12 of 13 models are currently active for BRKR. Of these, 2 models suggest upside while 10 models suggest overvaluation. The Bayesian DCF estimates BRKR's intrinsic value at $8.85, implying -85.0% downside from the current price. See which stocks rank higher →

How Does BRKR Rank in Laboratory Analytical Instruments?

Among 21 Laboratory Analytical Instruments stocks, BRKR ranks #3 by Quality of Company score. CirclFi's QOC score of 8.5/10 evaluates 32 fundamental signals. A score of 8.5 places BRKR in the top tier.

Bruker Corporation operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is BRKR a Value Trap?

CirclFi's Value Trap algorithm assigns BRKR a score of 25/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

12 of 13 models are active for Bruker Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Bruker Corporation's fundamental quality profile registers 8.5/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +115.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BRKR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BRKR's 12 active models, average confidence is 50%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Bruker Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Laboratory Analytical Instruments Stocks Should You Also Analyze?

8 related Laboratory Analytical Instruments stocks with 13-model coverage

Read investment analysis: MTD · AVTR · TXG · BIO · QTRX

Frequently Asked Questions About Bruker Corporation

What is Bruker Corporation's intrinsic value in 2026?

Based on CirclFi's 13-model analysis, Bruker Corporation (BRKR) has multiple fair value estimates. The Bayesian DCF model runs 10,000 Monte Carlo simulations with jump-diffusion to estimate intrinsic value at $8.85. The Quality of Company score is 8.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BRKR overvalued or undervalued right now?

At $58.97, 2 of 12 active models suggest BRKR may be undervalued, while 10 indicate potential overvaluation. The assessment depends on which methodology best fits Bruker Corporation's business model in Laboratory Analytical Instruments.

What does a Quality of Company score of 8.5 mean for BRKR?

Bruker Corporation's QOC of 8.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on BRKR?

CirclFi analyzes BRKR with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 12 of 13 are active for this stock. Read the full methodology →

Is BRKR a value trap in 2026?

Bruker Corporation's Value Trap score is 25/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 12 mathematical frameworks give you clarity on BRKR.

Unlock All 12 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access